Core Viewpoint - Dajiahui Kang's stock price closed at 11.81 yuan on July 29, 2025, reflecting a decrease of 0.16 yuan or 1.34% from the previous trading day [1] Group 1: Company Overview - Dajiahui Kang is a pharmaceutical commercial enterprise engaged in the wholesale and retail of drugs and medical devices [1] - The company's business spans multiple sectors, including pharmaceutical commerce and assisted reproduction [1] Group 2: Business Operations - As of July 29, the company reported that all business segments are operating normally and that various tasks are progressing in an orderly manner [1] - The company clarified that it does not manufacture ventilators, although some offline stores do sell them [1] Group 3: Market Activity - On July 29, the net outflow of main funds for Dajiahui Kang was 187,500 yuan, accounting for 0.01% of the circulating market value [1] - The trading volume for the day was 128,340 hands, with a total transaction amount of 154 million yuan [1]

证券日报网讯达嘉维康7月29日在互动平台回答投资者提问时表示，公司没有生产呼吸机产品，线下部 分门店有呼吸机销售。 （文章来源：证券日报） ...

证券日报网讯达嘉维康7月29日在互动平台回答投资者提问时表示，目前公司各业务板块生产经营正 常，各项工作有序推进中。二级市场的股价波动受宏观经济、政策环境、市场波动、投资者偏好等多重 因素影响。公司将不断努力做好经营，夯实基础，提升公司内在投资价值。 （文章来源：证券日报） ...

湖南启元律师事务所 关于湖南达嘉维康医药产业股份有限公司 2025年第二次临时股东会的 法律意见书 （一）本所律师出具本法律意见书是基于公司已承诺所有提供给本所律师的 文件的正本以及经本所律师查验与正本保持一致的副本均为真实、完整、可靠， 无隐瞒、虚假或重大遗漏之处。 （二）本所律师遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对 本法律意见书出具日以前已经发生或者存在的事实进行了充分的核查验证，保证 本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏。 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本法律意见，本所律师依法查验了公司提供的下列资料： 1、刊登在深圳证券交易所网站（http://www.szse.cn/）的与本次股东会有关的 通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、授权委托书等； 二零二五年七月二十八日 致：湖南达嘉维康医药产业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南达嘉维康医药产业股份 有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年 ...

湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 二、对外担保进展情况 证券代码：301126 证券简称：达嘉维康 公告编号：2025-049 近日，公司与石嘴山银行股份有限公司固原分行（以下简称"石嘴山银行"）、 中国民生银行股份有限公司银川分行（以下简称"民生银行"）分 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2025-048 湖南达嘉维康医药产业股份有限公司 关于 2023 年限制性股票与股票期权激励计划 部分股票期权注销完成的公告 特此公告。 湖南达嘉维康医药产业股份有限公司董事会 2025 年 7 月 21 日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日召开第四届董事会第十五次会议、第四届监事会第十二次会议，审议通过 了《关于 2023 年限制性股票与股票期权激励计划作废部分第二类限制性股票及 注销部分股票期权的议案》。根据公司《2023 年限制性股票与股票期权激励计 划（草案）》（以下简称"激励计划"）的规定，因存在第一个行权期公司层面 业绩考核未达成以及部分激励对象因个人原因离职的情形，公司需注销涉及 33 名激励对象已获授尚未行权的股票期权合计 1,344,000 份。具体内容详见公司于 2025 年 7 月 11 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于 2023 年 ...

Core Viewpoint - Dajia Weikang is expanding its market presence in East China through the acquisition of Anhui Dajia Weikang Health Pharmacy Co., Ltd. for 116 million yuan, aiming to enhance its competitive position despite facing declining profitability over the past three years [1][8]. Group 1: Acquisition Details - Dajia Weikang plans to acquire 60.85% of Anhui Dajia Weikang at a total valuation of 190 million yuan, reflecting a significant premium of 2776.97% over its book value [2][4]. - The acquisition will make Anhui Dajia Weikang a subsidiary of Dajia Weikang, with the latter holding 65% of its shares post-transaction [3][4]. - The deal includes performance commitments from the seller, requiring Anhui Dajia Weikang to achieve specific sales and profit targets over the next three years [4]. Group 2: Financial Performance - Despite rapid expansion, Dajia Weikang has experienced a decline in net profit for three consecutive years, with a total decrease of 61% from 2022 to 2024 [1][8]. - The company's revenue grew from 3.29 billion yuan in 2022 to 5.23 billion yuan in 2024, but net profit fell from 51.08 million yuan to 26.57 million yuan during the same period [8]. - In Q1 2025, Dajia Weikang reported revenue of 1.3 billion yuan, but net profit dropped by 83.82% year-on-year [8]. Group 3: Business Expansion - Dajia Weikang has rapidly expanded its store count from 121 in 2021 to 1389 by the end of 2024, marking a growth of approximately 10.5 times [6][7]. - The company operates 119 chain pharmacies under Anhui Dajia Weikang, focusing on retailing pharmaceuticals, health products, and medical devices [7]. - The retail business accounted for 51.44% of total revenue in 2024, with a year-on-year growth of 78.83% [7]. Group 4: Financial Health and Liabilities - As of March 2025, Anhui Dajia Weikang had total assets of approximately 108 million yuan and a debt ratio of 93.85%, indicating high leverage [5]. - Dajia Weikang's goodwill reached 1.135 billion yuan, constituting 17.6% of total assets and 61% of net assets, raising concerns about the sustainability of its acquisitions [9].

证券代码：301126 证券简称：达嘉维康 公告编号：2025-047 湖南达嘉维康医药产业股份有限公司 关于监事减持股份计划实施完毕的公告 公司监事唐娟保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"或"达嘉维康"）于 2025年5月14日披露了《关于董事、监事、高级管理人员减持股份的预披露公告》（公 告编号：2025-35），公司监事唐娟计划在减持股份预披露公告之日起15个交易日后 的3个月内（即2025年6月6日至2025年9月5日）以集中竞价交易方式减持本公司股份 不超过48,500股，占公司总股本比例不超过0.024%。 近日，公司收到唐娟女士出具的《关于股份减持计划实施进展的告知函》，唐 娟女士共计减持所持有公司股份48,500股，占公司总股本比例0.024%。截至本公告 披露日，唐娟女士本次股份减持计划已实施完毕，现将减持计划实施情况公告如下： 一、股东减持情况 | 股东名称 | 减持方式 | 减持 | 减持均价 | 减持股数 | 减持比例 | 股 ...

Mergers and Acquisitions - Dajia Weikang plans to acquire 60.85% equity of Anhui Dajia Weikang Health Pharmacy for a transaction price of 116 million yuan, making it a subsidiary post-transaction [1] - Jizhong Energy intends to purchase 49% equity of Jingneng Xilin Gol Energy for 669 million yuan, with the target company having a construction scale of 2×660MW efficient supercritical indirect air-cooled units [2] - Bomin Electronics has terminated its acquisition plan for Benchuang Electronics due to failure to reach consensus on key transaction terms [3] Shareholding Changes - Jingbeifang's employee shareholding platform plans to reduce its stake by up to 3% of the company's total shares, equating to a maximum of 26 million shares [4] - Sichuan Shuangma's major shareholders plan to collectively reduce their holdings by up to 2.92% of the company's total shares, amounting to approximately 1.11 million shares [5] - Chenghe Technology's shareholder, Shanghai Kehui Investment, intends to reduce its stake by up to 3% of the company's total shares, which is approximately 564,960 shares [6] Earnings Disclosure - China Merchants Heavy Industry expects a significant decline in net profit attributable to shareholders, projecting a decrease of 90.16% to 91.95%, with an estimated profit of 9 million to 11 million yuan [7] - Dongpeng Beverage anticipates a net profit increase of 33.48% to 41.57%, estimating a profit range of 2.31 billion to 2.45 billion yuan for the first half of 2025 [8] - Shuanglu Pharmaceutical forecasts a substantial net profit growth of 237.95% to 356.24%, estimating a profit of 100 million to 135 million yuan for the first half of 2025, primarily due to changes in the fair value of financial assets [10]